Clinical trial
Empagliflozin and the Preservation of Beta-cell Function in Women with Recent Gestational Diabetes
NCT03215069 is registered in ClinicalTrials.gov with Mount Sinai Hospital, Canada as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Empagliflozin and the Preservation of Beta-cell Function in Women with Recent Gestational Diabetes
- Lead sponsor
- Mount Sinai Hospital, Canada
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- July 1, 2018
- Completion date
- December 31, 2024
- Enrollment
- 91 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
gestational diabetes